Laddar populära aktier...
Q1e: orders -2%, sales +1% y-o-y, adj. EBITA margin 7.
Fallande ARR med hög tillströmning av nya kunder Med efterhängande covid-effekter fortsatte ARR att ...
Finnair’s Q1 earnings were in line with estimates even though top line came in a bit lower than esti...
Redeye comments on the update from the type C FDA meeting.
Cibus posted Q1 net operating income of EUR 28.1m, up 2% y/y and 1% below Infront consensus.
Atria reported Q1 adjusted EBIT of EUR 8.0m, 114% (EUR 4.
Redeye comments on Fantasma Games ahead of its Q1 results (due on 8 May).
Redeye publishes a follow-up note subsequent to yesterday's conference call concerning sunday's CRL ...
Redeye states the report aligned with its estimates, and Gasporox has now produced positive EBITDA s...
Q1 sales hurt by lower US sales, but other regions contributed well Fine-tuned sales estimates, but ...
Redeye comments on the announcement of a SEK120m rights issue of units.
Q1e a seasonally small quarter Divests loss-making business, EBITA margin +0.
Inför Q1-rapporten räknar Analysguiden med tillväxt på samtliga marknader och en stärkt rörelsemargi...
Redeye ser positivt på helgens nyhet att Eisai och BioArctic ingått ett forskningsutvärderingsavtal ...
Redeye anticipates that Physitrack will resume its sequential growth trajectory in Q1 2024, albeit w...